Targeted therapy to inhibit the oncogene FIP1L1-PDGFRα has met with some success: the first-generation tyrosine kinase inhibitor (TKI) imatinib has been reported to be effective to HES, but imatinib-resistant mutations emerged. The gene discussed is PDGFRA; the disease is hypereosinophilic syndrome.